Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Schrodinger Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Schrodinger (SDGR – Research Report), Lexicon Pharmaceuticals (LX...

Current Quarter	$-0.03	Next Quarter	$NA
Current Year	$-2.04	Next Year	$-0.92
QoQ Growth	NaN%	YoY Growth	+54.9%
3Y EPS CAGR	-21.9%	Target Price	$26.36
Consensus	Buy	Upside	+60.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SDGR	$16.47	+0.86%	1.38M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SDGR	$16.47	+0.9%	1.38M
3
4
5
6

SDGR

SDGR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Schrodinger Inc. Data in Excel

Get Schrodinger Inc. Data in Excel